  |
 | Up a level |
Plimack, Elizabeth R. and Rini, Brian I. and Stus, Viktor and Gafanov, Rustem and Waddell, Tom and Nosov, Dmitry and Pouliot, Frédéric and Soulieres, Denis and Melichar, Bohuslav and Vynnychenko, Ihor and Azevedo, Sergio Jobim and Borchiellini, Delphine and McDermott, Raymond S. and Bedke, Jens and Tamada, Satoshi and Yin, Lina and Chen, Mei and Molife, L. Rhoda and Atkins, Michael B. and Powles, Thomas (2020) Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. Journal of Clinical Oncology, Vol.38 (15supp). p. 5001. ISSN 1527-7755 (online, version of record) and 0732-183X (print)
Powles, Thomas and Plimack, Elizabeth R. and Soulieres, Denis and Waddell, Tom and Stus, Viktor and Gafanov, Rustem and Nosov, Dmitry and Pouliot, Frédéric and Melichar, Bohuslav and Vynnychenko, Ihor and Azevedo, Sergio J and Borchiellini, Delphine and McDermott, Raymond S and Bedke, Jens and Tamada, Satoshi and Yin, Lina and Chen, Mei and Molife, L Rhoda and Atkins, Michael B and Rini, Brian I (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. The Lancet Oncology, 21 (No. 12). pp. 1563-73. ISSN 1470-2045
Rugo, Hope S. and Barve, Abhijit and Waller, Cornelius F. and Hernandez-Bronchud, Miguel and Herson, Jay and Yuan, Jinyu and Sharma, Rajiv and Baczkowski, Mark and Kothekar, Mudgal and Loganathan, Subramanian and Manikhas, Alexey and Bondarenko, Igor and Mukhametshina, Guzel and Nemsadze, Gia and Parra, Joseph D and Abesamis Tiambeng, Maria Luisa T. and Baramidze, Kakhaber and Akewanlop, Charuwan and Vynnychenko, Ihor and Sriuranpong, Virote and Mamillapalli, Gopichand and Ray, Sirshendu and Ruiz, Eduardo P Yanez and Pennella, Eduardo (2017) Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer. A Randomized Clinical Trial. JAMA, 317 (1). pp. 37-47.
Al-Batran, Salah-Eddin and Schuler, Martin H. and Zvirbule, Zanete and Manikhas, Georgiy and Lordick, Florian and Rusyn, Andriy and Vynnyk, Yuriy and Vynnychenko, Ihor and Fadeeva, Natalia and Nechaeva, Marina and Dudov, Assen and Gotovkin, Evgeny and Pecheniy, Alexander and Bazin, Igor and Bondarenko, Igor and Melichar, Bohuslav and Mueller, Christian and Huber, Christoph and Tureci, Oezlem and Sahin, Ugur (2016) FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology, Vol 34 (No18_s). P.-LBA4001. ISSN 0732-183X (Print) ; 1527-7755 (Electronic) ; 0732-183X (Linking)
Rugo, Hope S. and Barve, Abhijit and Waller, Cornelius F. and Hernandez-Bronchud, Miguel and Herson, Jay and Yuan, Jinyu and Manikhas, Alexey and Bondarenko, Igor and Mukhametshina, Guzel and Nemsadze, Gia and Parra, Joseph D. and Tiambeng, Maria Luisa T. Abesamis and Baramidze, Kakhaber and Akewanlop, Charuwan and Vynnychenko, Ihor and Sriuranpong, Virote and Manillapalli, Gopichand and Ray, Sirshendu and Ruiz, Eduardo Patricio Yanez and Pennella, Eduardo J (2016) Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin. Journal of Clinical Oncology, Vol 34 (18_sup). P.-LBA503. ISSN 0732-183X (Print) ; 1527-7755 (Electronic) ; 0732-183X (Linking)
